CleaRank Financial AI • AI-powered analysis using real-time market data from TwelveData
Analysis reviewed by Roger Wohlner, Financial Journalist. Data refreshed daily. Not financial advice.
Biogen Inc. (BIIB) is trading at $232.83, above its 50-day SMA of $218.61 and 200-day SMA of $197.25, indicating a positive technical trend. The stock's 14-day RSI is at 63.7, signaling bullish momentum. Wall Street analysts maintain a 'Buy' consensus with a median price target of $240, suggesting a 3.1% upside. The company has a history of beating earnings estimates, with the most recent quarter showing a 77.34% EPS surprise. Forward-looking estimates suggest significant revenue and EPS growth in the coming years. Biogen's fundamental profile shows a profit margin of 8.32% and an operating margin of 25.06%, though its return on equity is 4.58%.
BIIB at a glance
Biogen Inc. (BIIB): Buy, 67/100 on CleaRank's AI score.
TrendUp: the price is above both its 50- and 200-day moving averages ($218.61 and $197.25).
EarningsBIIB beat estimates in 4 of its last 4 quarters, yet fell the next day after 3 of those beats.
InsidersInsiders sold $1.8M and bought $152K over the last 18 months.
ValuationP/E of 41.3 against 31.9 for the Healthcare sector: a premium to peers (+30%).
As of October 15, 2026, Biogen Inc. (BIIB) trades at $232.83. Wall Street's consensus target is $240.00 across 35 analysts. The 14-day RSI (daily closes) is 64, showing bullish momentum without being overbought, and the price is above its 50-day simple moving average of $218.61.
Figures as of October 15, 2026.
Only on CleaRank
Figures we compute ourselves from BIIB's own price, earnings and insider-filing history. Tap one to see it in context.
Trading at a significant premium to sector peers (+30%), suggesting market expectations for superior growth or market position.
BIIB Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
In the last 4 quarters, BIIB beat the analyst estimate 4 times; the stock fell in the first session after 3 of those beats.
BIIB earnings surprises and the stock's reaction
Report
EPS estimate
EPS actual
Surprise
First session
5 sessions
Jul 29, 2026
$2.03
$3.60
+77.34%
-0.62%
-1.24%
Apr 29, 2026
$2.95
$3.57
+21.02%
-2.62%
-1.90%
Feb 6, 2026
$1.62
$1.99
+22.84%
-3.66%
-2.32%
Oct 30, 2025
$3.88
$4.81
+23.97%
+3.11%
+4.77%
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
As of October 15, 2026, BIIB has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on July 29, 2026, came in 77.34% above the estimate and the stock moved -0.62% in the first session.
BIIB Analysis
Company's Health4/5
12-Month Analyst Target+3.08% above price
Median of 35 analysts (12-month)
$240.00
AI Analyst Consensus ScoreBuy
Biogen Inc. (BIIB) is trading above its 50-day simple moving average of $218.61 and its 200-day simple moving average of $197.25, indicating an uptrend. The 20-day exponential moving average is at $224.20, also below the current price, reinforcing bullish sentiment. The 14-day RSI is at 63.7, which is in the bullish territory, suggesting strong upward momentum. The MACD is positive at 2.82, further supporting the bullish technical picture. Key support levels are near the 50-day SMA at $218.61, while resistance may be found near recent highs. Volume has been above average recently, with the latest volume at 1.95 million compared to an average of 1.24 million, suggesting increased investor interest. The stochastic indicator is at 75.97, indicating the stock is approaching overbought conditions, which could signal a potential short-term pause or pullback.
ProTips
The stock is trading above its key moving averages (50-day SMA, 200-day SMA) with a bullish RSI, suggesting continued upward momentum. However, the stochastic indicator nearing overbought levels warrants caution for short-term traders.
Given the moderate insider selling, investors should closely watch for any further significant sell-offs. Consider position sizing carefully and setting appropriate stop-loss levels, potentially around 1.5x the daily volatility if it exceeds 5%.
Key Catalysts
BullishConsistent Earnings Beats
Biogen Inc. (BIIB) has a strong history of exceeding analyst EPS expectations, most recently with a 77.34% surprise in July 2026. This trend indicates strong operational performance and effective management.
Source: Earnings Reports
BullishPositive Revenue Growth Projections
Forward-looking estimates project a 14.00% year-over-year revenue growth for the next quarter, signaling continued expansion and market demand for Biogen's products.
Source: Analyst Estimates
BullishStrong Technical Momentum
The stock is trading above its 50-day and 200-day moving averages ($218.61 and $197.25) with a bullish RSI of 63.7, indicating a positive technical trend and potential for further price appreciation.
Source: Technical Analysis
BearishModerate Insider Selling Signal
Insiders have sold $1.8M in stock versus purchased $152.1K, resulting in a 'Moderate Sell Signal'. While not a 'Heavy Sell Signal', this indicates some lack of conviction from management.
The stochastic indicator is nearing 75.97, suggesting the stock may be overextended in the short term and could be due for a pullback or consolidation.
Source: Technical Analysis
Market Outlook
Biogen Inc. (BIIB) is expected to continue its positive trajectory, driven by strong earnings performance and projected revenue growth. The median analyst price target of $240 suggests a modest upside from the current price, reflecting confidence in the company's near-term prospects. The company's ability to consistently beat earnings estimates and its bullish technical indicators provide a solid foundation for continued performance. Key catalysts for upside include continued successful drug development and market penetration, as well as potential positive outcomes from ongoing clinical trials. Downside risks include the moderate insider selling signal and the stock approaching overbought technical levels, which could trigger a short-term correction. Also, any significant setbacks in drug pipelines or increased competition could impact future growth.
Key Statistics
Market Cap
34.40B
P/E Ratio
41.32
EPS (TTM)
5.54
Dividend Yield
0.00%
52 Week High
238.24
52 Week Low
138.00
As of October 15, 2026, BIIB trades at $232.83, with a market value of $34.40B and a P/E ratio of 41.32.
Biogen Inc. (BIIB) exhibits a mixed fundamental picture with a P/E ratio of 41.32, which is above the sector median of 31.9, but its price-to-sales ratio of 3.37 is below the sector average of 3.7. The company's profit margin is 8.32% and its operating margin is 25.06%, indicating efficient operations. However, its return on equity stands at 4.58%, which is below the sector median of 6.9. The company's debt-to-equity ratio is 0.44, in line with the sector median. While the current valuation appears somewhat stretched relative to its ROE and sector P/E, forward estimates suggest strong growth potential. Next year's EPS is projected to grow by 31.8% and revenue by 2.0%, with a 5-year average annual growth rate estimate of 10.7%. This growth outlook could justify the current valuation if realized.
Earnings & Growth Analysis
Biogen Inc. (BIIB) has demonstrated a strong track record of beating earnings estimates, with the most recent reported quarter (July 29, 2026) showing an EPS actual of $3.60 against an estimate of $2.04, a surprise of 77.34%. This follows consistent positive surprises in prior quarters, including 21.02% in April 2026 and 22.84% in February 2026. Despite these earnings beats, the stock experienced a slight decline of -0.62% following the latest earnings report. Revenue growth for the next quarter is projected at +14.00% year-over-year, indicating a positive top-line trajectory.
Key Risks
Biogen Inc. (BIIB) faces moderate selling pressure from insiders, with total sales significantly exceeding purchases, although the verdict is 'Moderate Sell Signal' rather than 'Heavy Sell Signal'. The company's return on equity of 4.58% is below the sector median, suggesting potential inefficiencies in generating profit from shareholder equity. Additionally, the stock's RSI is approaching overbought territory, which could indicate a risk of a short-term pullback.
Technical Indicators i
RSI (14-day)
63.70
MACD (12, 26)
2.82
SMA (50-day)
218.61
SMA (200-day)
197.25
Technical RatingBullish
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($218.61) above the 200-day SMA ($197.25), price action is firmly bullish above key moving averages.
As of October 15, 2026, with BIIB at $232.83, its 14-day RSI is 63.7 (showing bullish momentum without being overbought), its 50-day simple moving average is $218.61 and its 200-day is $197.25.
Calculated by CleaRank on daily closes as of October 15, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)+0.27
Weak correlation
Nasdaq 100 (QQQ)+0.17
Weak correlation
Bitcoin (BTC)+0.02
Weak correlation
Gold (XAU)+0.02
Weak correlation
As of October 15, 2026, BIIB's 1-year correlation of daily returns is +0.27 with S&P 500 (SPY), +0.17 with Nasdaq 100 (QQQ), +0.02 with Bitcoin (BTC) and +0.02 with gold (XAU).
Check Custom Correlation
How does any other asset move with BIIB? One year of daily closes, Pearson correlation.
Try
BIIB Wall Street View
12-month price targets
Low $175.00Median $240.00 (+3.1%)High $300.00
Ratings
Buy 22Hold 12Sell 13 months ago: 23 of 36 buy
Recent rating actions
Recent analyst rating actions on BIIB
Date
Firm
Action
Rating
Oct 9, 2026
UBS
Maintains
Buy
Oct 8, 2026
RBC Capital
Maintains
Outperform
Sep 10, 2026
HSBC
Maintains
Reduce
Sep 3, 2026
Piper Sandler
Reiterates
Overweight
Aug 25, 2026
RBC Capital
Maintains
Outperform
Aug 13, 2026
Wolfe Research
Upgrade
Outperform
As of October 15, 2026, 35 Wall Street analysts cover BIIB: 22 rate it a buy or strong buy, 12 a hold and 1 a sell or strong sell. Their 12-month price targets range from $175.00 to $300.00, with a median of $240.00, 3.1% above the price of $232.83.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
BIIB Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative2%Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$228.17
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$232.83
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$218.86
MAX LOSS
-4.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (63.7) and current market volatility
These levels come from BIIB's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Growth of $10,000
A $10,000 investment in BIIB in October 2016 would be worth about $7,983 today, compared with about $36,237 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
BIIB Drawdowns & Recovery
Worst fall, last 10 years
-71.2%
June 2021 to April 2025
Recovery
Not yet
still 41.3% below the June 2021 peak
From the 10-year high
-41.3%
highest close, June 2021
1-year holds that gained
45%
of every 1-year window
As of October 15, 2026, BIIB's worst peak-to-trough fall over the last 10 years was -71.2% (June 2021 to April 2025); it is still 41.3% below that peak, and 45% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BIIB today could grow to about $12,005 by 2036 in the base case, with a 90th-percentile outcome near $60,902 and a 10th-percentile outcome around $2,366. Projections are statistical simulations, not guarantees.
BIIB Stock Price Prediction: 2030
CleaRank's simulation projects a price near $250 for BIIB by 2030 in the base case, from $233 today (1.1x over 4 years). The 10th-percentile path ends near $89.69. These are outcomes of a Monte Carlo simulation run on BIIB's historical return distribution, not price targets, and they assume no dividends are reinvested.
BIIB simulated price paths by year
Year
10th percentile
Base case
90th percentile
2027
$142
$237
$396
2028
$117
$241
$499
2029
$101
$246
$599
2030
$89.69
$250
$700
2031
$80.91
$255
$804
Method: a lognormal simulation of BIIB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
As of October 15, 2026, BIIB insiders reported 6 open-market sales worth $1.8M and 2 open-market purchases worth $152K over the last 18 months; grants and option exercises are not counted.
Recent insider transactions in BIIB
Date
Insider
Type
Shares
Value
Oct 2, 2026
GODBOUT SEAN
Officer
Grant
27
-
Aug 4, 2026
MINOR LLOYD B.
Director
Sell
1.2K
$239.8K
Jun 9, 2026
FREIRE MARIA C
Director
Grant
2.0K
-
Jun 9, 2026
HAWKINS WILLIAM A III
Director
Grant
1.5K
-
Jun 9, 2026
LANGER SUSAN
Director
Grant
1.5K
-
Jun 9, 2026
MANTAS JESUS B
Director
Grant
1.5K
-
Jun 9, 2026
MINOR LLOYD B.
Director
Grant
1.5K
-
Jun 9, 2026
PANGALOS MENELAS N
Director
Grant
2.4K
-
Jun 9, 2026
PANGALOS MENELAS N
Director
Grant
1.5K
-
Jun 9, 2026
PATOLAWALA MONISH D
Director
Grant
1.5K
-
Page 1 of 1
Frequently Asked Questions
What is Biogen Inc.'s (BIIB) long-term outlook?
The long-term outlook for Biogen Inc. (BIIB) appears positive, with projected 5-year average annual growth of 10.7%.
How has Biogen Inc. (BIIB) performed in recent earnings reports?
Biogen Inc. (BIIB) has consistently beaten earnings estimates in recent quarters. The latest report on July 29, 2026, showed an EPS surprise of 77.34%. This strong earnings performance, coupled with projected revenue growth of 14.00% for the next quarter, supports a positive outlook.
What are the key technical indicators for Biogen Inc. (BIIB)?
Biogen Inc. (BIIB) is trading above its 50-day and 200-day moving averages ($218.61 and $197.25), indicating a bullish trend. The 14-day RSI is at 63.7 (bullish), and the MACD is positive at 2.82. However, the stochastic indicator is nearing overbought levels at 75.97, suggesting a potential for a short-term pause.
How does Biogen Inc.'s (BIIB) valuation compare to its sector peers?
Biogen Inc. (BIIB)'s P/E ratio of 41.32 is higher than the sector median of 31.9, but its price-to-sales ratio of 3.37 is below the sector average of 3.7. Its return on equity of 4.58% is also below the sector median of 6.9, indicating potential for valuation concerns despite strong growth prospects.
What is the projected revenue growth for Biogen Inc. (BIIB)?
Biogen Inc. (BIIB) is projected to achieve revenue growth of +14.00% for the next quarter and +6.00% for the current year. Looking further ahead, revenue is expected to grow by 2.00% in the next year, with a 5-year average annual growth rate estimate of 10.7%.
Are insiders buying or selling BIIB?
Selling, on balance. In the last 18 months, BIIB's officers, directors and large holders reported 6 sales worth $1.8M and 2 open-market purchases worth $152K. Grants and option exercises are not counted as buying.
What is the analyst price target for BIIB?
As of October 15, 2026, the 35 Wall Street analysts covering BIIB have 12-month targets from $175.00 to $300.00, with a median of $240.00, 3.1% above the current price of $232.83. 22 rate it a buy or strong buy, 12 a hold and 1 a sell or strong sell. Three months ago 23 of 36 rated it a buy.
What is BIIB's biggest drop in the last 10 years?
Biogen Inc. (BIIB)'s worst peak-to-trough fall over the last 10 years was -71.2%, from June 2021 to April 2025. It has not regained that peak yet and is still 41.3% below it. Over the same period, 45% of 1-year holding periods ended with a gain.
What are BIIB's best and worst months?
Over the last 10 years, June has been BIIB's strongest month on average (+4.22%, rising in 7 of 10 years) and March its weakest (-5.82%, rising in 2 of 10 years). Seasonal averages describe the past and do not predict a given year.
How closely does BIIB move with the stock market?
Over the past year BIIB's daily returns were weakly correlated with the S&P 500 (SPY) (+0.27). Nasdaq 100 (QQQ): +0.17; Bitcoin (BTC): +0.02; Gold (XAU): +0.02. A figure near +1 means the two usually move together; near 0 means little relationship.
